An Open-label, Uncontrolled Study of ONO-4578 and ONO-4538 in Combination With Standard-of-care Modified FOLFIRINOX (mFFX) or Gemcitabine Plus Nab-paclitaxel (GnP) Therapy as First-line Treatment in Patients With Metastatic Pancreatic Cancer

• Status: COMPLETED
• Trial end date: 2025-01-30

Summary

This study is a multicenter, open-label, uncontrolled study to investigate the tolerability and safety of ONO-4578, ONO-4538, and standard of care in combination as first-line treatment in patients with metastatic pancreatic cancer.

• Phase: PHASE1

Details

• Lead Sponsor: Ono Pharmaceutical Co. Ltd
• Treatments: 130-nm albumin-bound paclitaxel; Fluorouracil; Gemcitabine; Irinotecan; Leucovorin; Nivolumab; Oxaliplatin